{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T07:12:02Z","timestamp":1777014722618,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:00:00Z","timestamp":1556150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11033-019-04788-6","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T19:35:27Z","timestamp":1556220927000},"page":"4685-4697","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Inhibitory effect of carbonyl reductase 1 against peritoneal progression of ovarian cancer: evaluation by ex vivo 3D-human peritoneal model"],"prefix":"10.1007","volume":"46","author":[{"given":"Hiroe","family":"Oikiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Asano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiya","family":"Matsusaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5214-512X","authenticated-orcid":false,"given":"Yoshihito","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,25]]},"reference":[{"issue":"1","key":"4788_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11\u201330","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 1","key":"4788_CR2","doi-asserted-by":"publisher","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","volume":"95","author":"AP Heintz","year":"2006","unstructured":"Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT et al (2006) Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S161\u2013S192","journal-title":"Int J Gynaecol Obstet"},{"issue":"9","key":"4788_CR3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","volume":"27","author":"MA Bookman","year":"2009","unstructured":"Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M et al (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27(9):1419\u20131425","journal-title":"J Clin Oncol"},{"issue":"2","key":"4788_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3892\/mco.2013.223","volume":"2","author":"Y Yokoyama","year":"2014","unstructured":"Yokoyama Y, Futagami M, Watanabe J, Sato N, Terada Y, Miura F et al (2014) Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer. Mol Clin Oncol 2(2):212\u2013218","journal-title":"Mol Clin Oncol"},{"issue":"6","key":"4788_CR5","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1124\/dmd.107.014779","volume":"35","author":"V Gonzalez-Covarrubias","year":"2007","unstructured":"Gonzalez-Covarrubias V, Ghosh D, Lakhman SS, Pendyala L, Blanco JG (2007) A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity. Drug Metab Dispos 35(6):973\u2013980","journal-title":"Drug Metab Dispos"},{"issue":"31","key":"4788_CR6","doi-asserted-by":"crossref","first-page":"16185","DOI":"10.1016\/S0021-9258(18)37576-8","volume":"263","author":"B Wermuth","year":"1988","unstructured":"Wermuth B, Bohren KM, Heinemann G, von Wartburg JP, Gabbay KH (1988) Human carbonyl reductase: nucleotide sequence analysis of a cDNA and amino acid sequence of the encoded protein. J Biol Chem 263(31):16185\u201316188","journal-title":"J Biol Chem"},{"issue":"4","key":"4788_CR7","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1158\/1535-7163.MCT-06-0722","volume":"6","author":"Y Yokoyama","year":"2007","unstructured":"Yokoyama Y, Xin B, Shigeto T, Umemoto M, Kasai-Sakamoto A, Futagami M et al (2007) Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther 6(4):1379\u20131386","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"4788_CR8","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1054\/bjoc.2001.2034","volume":"85","author":"M Umemoto","year":"2001","unstructured":"Umemoto M, Yokoyama Y, Sato S, Tsuchida S, Al-Mulla F, Saito Y (2001) Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer. Br J Cancer 85(7):1032\u20131036","journal-title":"Br J Cancer"},{"key":"4788_CR9","first-page":"105","volume":"6","author":"H Wang","year":"2012","unstructured":"Wang H, Yokoyama Y, Tsuchida S, Mizunuma H (2012) Malignant ovarian tumors with induced expression of carbonyl reductase show spontaneous regression. Clin Med Insights Oncol 6:105\u2013107","journal-title":"Clin Med Insights Oncol"},{"issue":"3","key":"4788_CR10","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3892\/ijo.2014.2810","volume":"46","author":"Y Osawa","year":"2015","unstructured":"Osawa Y, Yokoyama Y, Shigeto T, Futagami M, Mizunuma H (2015) Decreased expression of carbonyl reductase 1 promotes ovarian cancer growth and proliferation. Int J Oncol 46(3):1252\u20131258","journal-title":"Int J Oncol"},{"issue":"6","key":"4788_CR11","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.3892\/ijo.2015.3205","volume":"47","author":"R Miura","year":"2015","unstructured":"Miura R, Yokoyama Y, Shigeto T, Futagami M, Mizunuma H (2015) Inhibitory effect of carbonyl reductase 1 on ovarian cancer growth via tumor necrosis factor receptor signaling. Int J Oncol 47(6):2173\u20132180","journal-title":"Int J Oncol"},{"issue":"7","key":"4788_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S1461-5347(00)00273-X","volume":"3","author":"JD Eichman","year":"2000","unstructured":"Eichman JD, Bielinska AU, Kukowska-Latallo JF, Baker JR Jr (2000) The use of PAMAM dendrimers in the efficient transfer of genetic material into cells. Pharm Sci Technol Today 3(7):232\u2013245","journal-title":"Pharm Sci Technol Today"},{"issue":"12","key":"4788_CR13","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/jgm.1258","volume":"10","author":"HL Fu","year":"2008","unstructured":"Fu HL, Cheng SX, Zhang XZ, Zhuo RX (2008) Dendrimer\/DNA complexes encapsulated functional biodegradable polymer for substrate-mediated gene delivery. J Gene Med 10(12):1334\u20131342","journal-title":"J Gene Med"},{"issue":"1","key":"4788_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/cgt.2015.61","volume":"23","author":"A Kobayashi","year":"2016","unstructured":"Kobayashi A, Yokoyama Y, Osawa Y, Miura R, Mizunuma H (2016) Gene therapy for ovarian cancer using carbonyl reductase 1 DNA with a polyamidoamine dendrimer in mouse models. Cancer Gene Ther 23(1):24\u201328","journal-title":"Cancer Gene Ther"},{"issue":"1\u20132","key":"4788_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.bbrc.2017.10.050","volume":"494","author":"Y Asano","year":"2017","unstructured":"Asano Y, Odagiri T, Oikiri H, Matsusaki M, Akashi M, Shimoda H (2017) Construction of artificial human peritoneal tissue by cell-accumulation technique and its application for visualizing morphological dynamics of cancer peritoneal metastasis. Biochem Biophys Res Commun 494(1\u20132):213\u2013219","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"4788_CR16","first-page":"592","volume":"47","author":"Y Kikuchi","year":"1987","unstructured":"Kikuchi Y, Kizawa I, Oomori K, Miyauchi M, Kita T, Sugita M et al (1987) Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation. Cancer Res 47(2):592\u2013596","journal-title":"Cancer Res"},{"issue":"60","key":"4788_CR17","doi-asserted-by":"publisher","first-page":"e3888","DOI":"10.3791\/3888","volume":"17","author":"RA Davidowitz","year":"2012","unstructured":"Davidowitz RA, Iwanicki MP, Brugge JS (2012) In vitro mesothelial clearance assay that models the early steps of ovarian cancer metastasis. J Vis Exp 17(60):e3888. https:\/\/doi.org\/10.3791\/3888","journal-title":"J Vis Exp"},{"issue":"10","key":"4788_CR18","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1038\/oncsis.2016.64","volume":"5","author":"JN Sheets","year":"2016","unstructured":"Sheets JN, Iwanicki M, Liu JF, Howitt BE, Hirsch MS, Gubbels JA et al (2016) SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance. Oncogenesis 5(10):e264","journal-title":"Oncogenesis"},{"issue":"2","key":"4788_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1158\/2159-8274.CD-11-0010","volume":"1","author":"MP Iwanicki","year":"2011","unstructured":"Iwanicki MP, Davidowitz RA, Ng MR, Besser A, Muranen T, Merritt M et al (2011) Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov 1(2):144\u2013157","journal-title":"Cancer Discov"},{"key":"4788_CR20","doi-asserted-by":"publisher","first-page":"14470","DOI":"10.1038\/ncomms14470","volume":"8","author":"A Yokoi","year":"2017","unstructured":"Yokoi A, Yoshioka Y, Yamamoto Y, Ishikawa M, Ikeda SI, Kato T et al (2017) Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer. Nat Commun 8:14470","journal-title":"Nat Commun"},{"key":"4788_CR21","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1172\/JCI69815","volume":"124","author":"RA Davidowitz","year":"2014","unstructured":"Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H et al (2014) Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced\u00a0mesothelial clearance. J Clin Invest 124:2611\u20132625","journal-title":"J Clin Invest"},{"key":"4788_CR22","doi-asserted-by":"publisher","first-page":"25115","DOI":"10.18632\/oncotarget.25344","volume":"9","author":"KM Gharpure","year":"2018","unstructured":"Gharpure KM, Lara OD, Wen Y, Pradeep S, LaFargue C, Ivan C et al (2018) ADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget 9:25115\u201325126","journal-title":"Oncotarget"},{"issue":"8","key":"4788_CR23","first-page":"1629","volume":"60","author":"H Kajiyama","year":"2008","unstructured":"Kajiyama H (2008) A new strategy for overcoming peritoneal metastasis and drug resistance in epithelial ovarian cancer by inhibition of EMT (epithelial-mesenchymal transition). Acta Obst Gynaec Jpn 60(8):1629\u20131640","journal-title":"Acta Obst Gynaec Jpn"},{"issue":"2","key":"4788_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nchembio711","volume":"1","author":"A Degterev","year":"2005","unstructured":"Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al (2005) Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 1(2):112\u2013119","journal-title":"Nat Chem Biol"},{"issue":"1","key":"4788_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/imr.12541","volume":"277","author":"B Tummers","year":"2017","unstructured":"Tummers B, Green DR (2017) Caspase-8: regulating life and death. Immunol Rev 277(1):76\u201389","journal-title":"Immunol Rev"},{"issue":"10","key":"4788_CR26","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.1073\/pnas.93.10.4897","volume":"93","author":"JF Kukowska-Latallo","year":"1996","unstructured":"Kukowska-Latallo JF, Bielinska AU, Johnson J, Spindler R, Tomalia DA, Baker JR Jr (1996) Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc Natl Acad Sci USA 93(10):4897\u20134902","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"4788_CR27","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.tiv.2014.07.014","volume":"28","author":"MA Maher","year":"2014","unstructured":"Maher MA, Naha PC, Mukherjee SP, Byrne HJ (2014) Numerical simulations of in vitro nanoparticle toxicity\u2014the case of poly(amido amine) dendrimers. Toxicol In Vitro 28(8):1449\u20131460","journal-title":"Toxicol In Vitro"},{"issue":"2","key":"4788_CR28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.nano.2012.05.002","volume":"9","author":"SP Mukherjee","year":"2013","unstructured":"Mukherjee SP, Byrne HJ (2013) Polyamidoamine dendrimer nanoparticle cytotoxicity, oxidative stress, caspase activation and inflammatory response: experimental observation and numerical simulation. Nanomedicine 9(2):202\u2013211","journal-title":"Nanomedicine"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-019-04788-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11033-019-04788-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-019-04788-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T22:08:00Z","timestamp":1663366080000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11033-019-04788-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,25]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["4788"],"URL":"https:\/\/doi.org\/10.1007\/s11033-019-04788-6","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,25]]},"assertion":[{"value":"16 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}